Dr Reddy's Laboratories (NSE:DRREDDY) Cyclically Adjusted Revenue per Share: ₹324.86 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:DRREDDY Dr Reddy's Laboratories Ltd NSE:DRREDDY
93 GF Score
Price ₹1,180.00
GF Value ₹1,368.80
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share?

Dr Reddy's Laboratories NSE:DRREDDY +2.78% 93 Cyclically Adjusted Revenue per Share is ₹324.86 as of Jun. 2026. GuruFocus rates NSE:DRREDDY with a GF Score™ of 93/100 and a GF Value™ of ₹1,368.80 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Dr Reddy's Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was ₹96.810. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹324.86 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Dr Reddy's Laboratories's average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Dr Reddy's Laboratories was 18.80% per year. The lowest was 5.80% per year. And the median was 8.40% per year.

As of today (2026-08-04), Dr Reddy's Laboratories's current stock price is ₹1180.00. Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹324.86. Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is 3.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.17. The lowest was 2.27. And the median was 3.84.


Dr Reddy's Laboratories  (NSE:DRREDDY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1180.00/324.86
=3.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.17. The lowest was 2.27. And the median was 3.84.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Related Terms


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Chart

Dr Reddy's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 236.20 256.30 274.70 293.40 317.53

Dr Reddy's Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 300.60 308.58 313.67 317.53 324.86

NSE:DRREDDY vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:DRREDDY
93GF Score
Dr Reddy's Laboratories Ltd NSE:DRREDDY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dr Reddy's Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=96.81/166.1454*166.1454
=96.810

Current CPI (Jun. 2026) = 166.1454.

Dr Reddy's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 43.174 105.961 67.696
201612 44.658 105.196 70.532
201703 42.851 105.196 67.678
201706 39.948 107.109 61.967
201709 42.691 109.021 65.060
201712 45.822 109.404 69.587
201803 42.531 109.786 64.364
201806 44.785 111.317 66.844
201809 45.697 115.142 65.939
201812 46.356 115.142 66.890
201903 48.377 118.202 67.999
201906 46.287 120.880 63.620
201909 57.848 123.175 78.029
201912 52.895 126.235 69.618
202003 53.338 124.705 71.063
202006 53.166 127.000 69.553
202009 58.879 130.118 75.182
202012 59.255 130.889 75.216
202103 56.873 131.771 71.709
202106 59.191 134.084 73.344
202109 69.309 135.847 84.767
202112 63.972 138.161 76.930
202203 65.293 138.822 78.144
202206 62.711 142.347 73.195
202209 75.807 144.661 87.065
202212 81.375 145.763 92.754
202303 75.652 146.865 85.584
202306 80.928 150.280 89.472
202309 82.652 151.492 90.647
202312 86.542 152.924 94.024
202403 84.897 153.035 92.170
202406 91.995 155.789 98.111
202409 96.108 157.882 101.138
202412 100.187 158.323 105.137
202503 101.967 157.552 107.529
202506 102.581 159.755 106.684
202509 105.683 162.289 108.194
202512 104.739 163.281 106.577
202603 90.167 164.272 91.195
202606 96.810 166.145 96.810

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹324.86 mean?
Dr Reddy's Laboratories (NSE:DRREDDY) has a Cyclically Adjusted Revenue per Share of ₹324.86 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dr Reddy's Laboratories and its competitors.
Is Dr Reddy's Laboratories' Cyclically Adjusted Revenue per Share too high?
Dr Reddy's Laboratories' current Cyclically Adjusted Revenue per Share is ₹324.86. Overall, Dr Reddy's Laboratories has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS?
Dr Reddy's Laboratories' Cyclically Adjusted Revenue per Share of ₹324.86 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dr Reddy's Laboratories and its competitors. Dr Reddy's Laboratories's current Cyclically Adjusted Revenue per Share is ₹324.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (NSE:DRREDDY) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,368.80, compared to a current price of ₹1,180.00 — trading 13.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹324.86. Dr Reddy's Laboratories' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Dr Reddy's Laboratories (NSE:DRREDDY), the current Cyclically Adjusted Revenue per Share is ₹324.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr Reddy's Laboratories (NSE:DRREDDY) Overvalued in 2026?

Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued. The current stock price of ₹1,180.00 is trading 13.8% below its estimated GF Value™ of ₹1,368.80. GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.

Key valuation signals for NSE:DRREDDY:

  • Cyclically Adjusted Revenue per Share: ₹324.86
  • GF Value™: ₹1,368.80 vs. price of ₹1,180.00 (13.8% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the NSE:DRREDDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dr Reddy's Laboratories Business Description

Address 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
93GF Score

Get the complete analysis for NSE:DRREDDY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,180.00
Price
₹1,368.80
GF Value